Evidence map›Paper›PMID 34944062›Full record

ArticleCells2021

Attenuation of Pancreatic Cancer In Vitro and In Vivo via Modulation of Nrf2 and NF-κB Signaling Pathways by Natural Compounds.

Marta Cykowiak, Robert Kleszcz, Małgorzata Kucińska, Jarosław Paluszczak, Hanna Szaefer, Adam Plewiński, Hanna Piotrowska-Kempisty, Marek Murias, Violetta Krajka-Kuźniak

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Frontiers in pharmacology · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marta CykowiakDepartment of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 4, Święcickiego Street, 60-781 Poznań, Poland.ORCID 0000-0002-8152-7140
Robert KleszczDepartment of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 4, Święcickiego Street, 60-781 Poznań, Poland.ORCID 0000-0002-6607-7436
Małgorzata KucińskaDepartment of Toxicology, Poznan University of Medical Sciences, 30, Dojazd Street, 60-631 Poznań, Poland.ORCID 0000-0002-3606-3623
Jarosław PaluszczakDepartment of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 4, Święcickiego Street, 60-781 Poznań, Poland.ORCID 0000-0002-6187-7549
Hanna SzaeferDepartment of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 4, Święcickiego Street, 60-781 Poznań, Poland.ORCID 0000-0001-5875-3425
Adam PlewińskiCentre for Advanced Technologies, Adam Mickiewicz University, 10, Uniwersytetu Poznańskiego Street, 61-614 Poznań, Poland.
Hanna Piotrowska-KempistyDepartment of Toxicology, Poznan University of Medical Sciences, 30, Dojazd Street, 60-631 Poznań, Poland.
Marek MuriasDepartment of Toxicology, Poznan University of Medical Sciences, 30, Dojazd Street, 60-631 Poznań, Poland.ORCID 0000-0002-2903-4912
Violetta Krajka-KuźniakDepartment of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 4, Święcickiego Street, 60-781 Poznań, Poland.ORCID 0000-0001-7275-0298
Poznan University of Medical Sciences · PLAdam Mickiewicz University in Poznań · PL

Funding

National Science Center 2016/21/B/NZ5/01390
6 · The paper itself

Abstract

Pancreatic cancer is a disease in which deregulation of signaling pathways plays a key role, thus searching for their novel modulators is a promising therapeutic strategy. Hence, in this study, the effect of phytochemical combinations on the canonical and non-canonical activation of Nrf2 and its interaction with the NF-κB pathway was evaluated in extensively proliferating pancreatic cancer cell line, PSN-1, in comparison to non-cancerous MS1 cells. The activation of Nrf2 and NF-κB, expression of their target genes, and effect on cell survival were assessed in PSN-1 cells. The tumor burden was evaluated in mice carrying xenografts. PSN-1 cells were more sensitive to the tested compounds as compared to the MS1 cell line. Combination of xanthohumol and phenethyl isothiocyanate was more effective than single compounds at decreasing the canonical and non-canonical activation of Nrf2 in PSN-1 cancer cells. Decreased activation of NF-κB, and subsequent reduced cytosolic COX-2 and nuclear STAT3 level indicated their anti-inflammatory and pro-apoptotic activities. In vivo studies showed the partial response in groups treated with xanthohumol or the combination of xanthohumol and phenethyl isothiocyanate. Overall, these results suggest that the combination of xanthohumol and phenethyl isothiocyanate may be a promising therapeutic candidate against pancreatic cancer.

Indexed as

AnimalsApoptosisBiological ProductsCell Line, TumorCell ProliferationCell SurvivalCyclooxygenase 2Drug SynergismFlavonoidsHumansIsothiocyanatesMiceNF-E2-Related Factor 2NF-kappa BPancreatic NeoplasmsPhytochemicalsBiological ProductsCyclooxygenase 2FlavonoidsIsothiocyanatesNFE2L2 protein, humanNF-E2-Related Factor 2NF-kappa Bphenethyl isothiocyanatePhytochemicalsPropiophenonesSTAT3 protein, humanSTAT3 Transcription Factorxanthohumolcanonical and non-canonical Nrf2 pathwaymice xenograft modelMS1 cellsNF-κB pathwayphytochemicalsPSN-1 cells

Identifiers

PMID34944062
PMCPMC8700195
OpenAlexW4200227095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.